NCT06431893View on ClinicalTrials.gov

A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Homocystinuria
Interventions
DRUG

Pegtibatinase

Full Target Dose of pegtibatinase BIW

Trial Locations (4)

10029

Travere Investigational Site, New York

19104

Travere Investigational Site, Philadelphia

27560

Travere Investigational Site - Virtual Site, Morrisville

04012

Travere Investigational Site, Portland

All Listed Sponsors
lead

Travere Therapeutics, Inc.

INDUSTRY